Last 46 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -5.82 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 79.68 | 7.27 | 5.33 | 13.13 | 36.92 | 32.89 | 125.05 | — | — | — | — | — | — |
| — | -77.9% | -95.7% | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 6.45 | 11.55 | 5.14 | 4.89 | 3.94 | 4.49 | 4.03 | 4.12 | 2.83 | 2.82 | 3.64 | 3.37 | 3.44 |
| — | +157.3% | +27.5% | +18.7% | +39.2% | +58.9% | +10.6% | +22.4% | -17.8% | -34.5% | +13.9% | +23.0% | +20.7% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Syndax Pharmaceuticals, Inc.'s operating margin was -125.2% in Q3 2025, up 57.5 pp QoQ and up 591.4 pp YoY. This marks the 4th consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -495.1% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 13.9% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.5% | 86.1% | 96.6% | 95.6% | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — |
| — | -13.9% | -3.4% | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -1434.4% | -125.2% | -182.7% | -417.9% | -1254.8% | -716.6% | -2120.5% | — | — | — | — | — | — |
| — | +82.5% | +91.4% | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -1346.1% | -132.4% | -189.3% | -423.3% | -1226.2% | -673.0% | -1944.7% | — | — | — | — | — | — |
| — | +80.3% | +90.3% | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -75.7% | -44.5% | -38.6% | -33.7% | -28.8% | -21.0% | -14.7% | -13.8% | -15.9% | -13.5% | -10.7% | -9.1% | -9.7% |
| — | -111.8% | -162.5% | -143.6% | -81.3% | -55.9% | -37.6% | -52.0% | -63.1% | -33.2% | -4.7% | +4.1% | -130.7% | |
| ROA | -47.7% | -10.6% | -11.6% | -12.4% | -16.4% | -18.6% | -13.3% | -12.5% | -14.3% | -12.3% | -10.0% | -8.6% | -9.1% |
| — | +43.2% | +12.9% | +0.8% | -14.3% | -51.3% | -33.3% | -45.8% | -56.6% | -33.3% | -10.4% | -0.8% | -132.8% | |
| ROIC | -68.8% | -21.8% | -91.8% | -23.2% | -20.2% | -23.8% | -15.7% | -18.7% | -22.2% | -14.8% | -10.9% | -8.9% | -9.5% |
| — | +8.3% | -484.2% | -24.1% | +8.7% | -60.9% | -44.2% | -109.1% | -132.9% | -49.0% | +9.6% | +33.1% | -123.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 33.6% YoY to 4.64x, tightening the short-term liquidity position. Debt/Equity has risen for 3 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.20 | 2.99 | 0.01 | 0.01 | 1.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
| — | +128280.9% | +308.9% | +202.7% | +40576.8% | -55.2% | -50.4% | +16.0% | +18.8% | +40.0% | -91.0% | -95.7% | -95.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.82 | 4.64 | 4.71 | 5.80 | 5.82 | 6.99 | 10.50 | 8.93 | 10.00 | 9.73 | 13.56 | 18.61 | 16.85 |
| — | -33.6% | -55.2% | -35.0% | -41.8% | -28.2% | -22.5% | -52.0% | -40.7% | -43.4% | +6.9% | +35.4% | -22.3% | |
| Quick Ratio | 5.82 | 4.40 | 4.55 | 5.75 | 5.82 | 6.99 | 10.50 | 8.93 | 10.00 | 9.73 | 13.56 | 18.61 | 16.85 |
| — | -37.0% | -56.7% | -35.6% | -41.8% | -28.2% | -22.5% | -52.0% | -40.7% | -43.4% | +6.9% | +35.4% | -22.3% | |
| Interest Coverage | -68.91 | -19.05 | -8.83 | -10.40 | -20.05 | -3894.65 | -1649.24 | -1445.71 | -1236.59 | -805.07 | -1419.37 | -1150.38 | -977.51 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonSyndax Pharmaceuticals, Inc.'s current P/E is -5.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Syndax Pharmaceuticals, Inc.'s current operating margin is -1434.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Syndax Pharmaceuticals, Inc.'s business trajectory between earnings reports.